NCT07155382View on ClinicalTrials.gov

Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1

CompletedOBSERVATIONAL
Enrollment

98

Participants

Timeline

Start Date

April 4, 2017

Primary Completion Date

May 27, 2024

Study Completion Date

August 22, 2024

Conditions
Acute Myeloid Leukemia (AML)
Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT07155382 - Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1 | Biotech Hunter | Biotech Hunter